Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech/Novartis Xolair Indication Narrowed To Adult Allergic Asthma

Executive Summary

Genentech and Novartis will seek a narrower label for the asthma biologic Xolair following the receipt of a "complete response" letter from FDA July 5.
Advertisement

Related Content

Xolair Allergic Asthma Population Should Not Be Restricted Except By Age
Xolair Allergic Asthma Population Should Not Be Restricted Except By Age
Genentech/OSI Tarceva Lung Cancer Trial Modified Following “Safety Signal”
Genentech/OSI Tarceva Lung Cancer Trial Modified Following “Safety Signal”
Genentech/Novartis Xolair BLA Resubmission Planned For 2002
Novartis Zomaril NDA Filing Awaits More Data On QTc Prolongation
Genentech Xanelim Therapy Transition Study To Support Product Launch
Genentech, FDA Discussing Herceptin Label Changes To Reflect New PK Data
Genentech/Novartis Xolair Approval Could Be Delayed Until Early 2002
Genentech/Novartis Xolair Approval Could Be Delayed Until Early 2002
Advertisement
UsernamePublicRestriction

Register

PS038178

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel